secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-08-03T11:05:25+00:00
Accession:  0001493152-26-035741
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix receives FDA alignment on Phase 2 study design for TNX-4800 Lyme disease prevention
--------------------------------------------------------------------------------

- FDA aligned on adaptive Phase 2 field study of TNX-4800 enrolling 3,300 adults over two seasons.
- Primary efficacy endpoint: Lyme disease prevention at 6 months; key secondary at 3 months.
- Manufacturing of investigational product on track for delivery to study sites in Q1 2027.
- TNX-4800 is a long-acting human monoclonal antibody targeting OspA, with potential advantages over vaccines.
- Majority of enrollment expected in 2028 season; may extend to 2029 if attack rate lower.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226035741/0001493152-26-035741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226035741/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer